

Patient: [REDACTED]
 DOB: [REDACTED] Age: 15 Gender: M
 Patient Identifiers: [REDACTED]
 Visit Number (FIN): [REDACTED]

Client: [REDACTED]
 Physician: [REDACTED]

ARUP Test Code: 2005016
 Collection Date: 10/18/2019
 Received in lab: 10/19/2019
 Completion Date: 10/21/2019

Patient Result Summary

Result: Detected

BCR-ABL1/ABL1 Ratio: 0.00253

BCR-ABL1 fusion transcripts (p190 form) were detected by RT-qPCR. This result has been reviewed and approved by Jay Patel, M.D.

Patient History Results

Collected On	Ratio	Result	Source
10/18/19	0.00153	Detected	Bone Marrow
10/18/19	0.00253	Detected	Whole Blood
09/18/19	0.00533	Detected	Bone Marrow

-See previous individual reports for details on specific test results.

-Historical data is not provided for specimens ordered prior to May 16, 2011.

-Consecutive test results are displayed on this chart; however, this result set may be incomplete due to variations in the demographic information submitted for prior tests. If the information shown on this chart appears incomplete, please consult this patient's prior charts.

Test Information

Background

This assay quantifies BCR-ABL1 transcripts (e1a2) for diagnosis and ongoing therapeutic monitoring. BCR-ABL1 translocations with BCR breakpoints in the minor breakpoint cluster region result in the p190 fusion protein and are predominantly seen in acute lymphoblastic leukemia (ALL) although they may be present in rare cases of chronic myelogenous leukemia (CML).

Methods

Total RNA is isolated and converted to cDNA and BCR-ABL1 fusions are quantitated by real-time PCR amplification. The primers are designed to detect the minor (p190) BCR-ABL1 breakpoint with a fusion between BCR exon 1 and ABL1 exon 2 (e1a2). Each PCR assay includes a standard curve for BCR-ABL1 and the ABL1 control and a normalized copy number (NCN) is calculated (# BCR-ABL1 cDNA molecules/# ABL1 cDNA molecules).

Limitations

The limit of detection of this assay is 1 BCR-ABL1 positive cell in 125,000 normal cells. The results of this test must always be interpreted in the context of morphologic and other relevant data and should not be used alone for a diagnosis of malignancy.

Compliance

Test developed and characteristics determined by ARUP Laboratories. See Compliance Statement D: aruplab.com/CS



Patient: [REDACTED]
 ARUP Accession: 19-291-115552